Identification
- Summary
Desvenlafaxine is an antidepressant agent and SNRI used for the treatment of major depressive disorders in adults.
- Brand Names
- Pristiq
- Generic Name
- Desvenlafaxine
- DrugBank Accession Number
- DB06700
- Background
Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) classLabel. Desvenlafaxine may be used to treat major depressive disorderLabel. It is formulated as an extended release tabletLabel. Desvenlafaxine was approved by the FDA in 20087.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Desvenlafaxine (DB06700)
- Weight
- Average: 263.3752
Monoisotopic: 263.188529049 - Chemical Formula
- C16H25NO2
- Synonyms
- Desvenlafaxina
- Desvenlafaxine
- O-desmethylvenlafaxine
- ODV
- External IDs
- DVS 233
Pharmacology
- Indication
Desvenlafaxine is indicated for the treatment of major depressive disorder in adults3,4,Label.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Desvenlafaxine is a selective serotonin and norepinephrine reuptake inhibitor3,4,Label. It lacks significant activity on muscarinic-cholinergic, H1-histaminergic, or α1-adrenergic receptors in vitro. Desvenlafaxine does not appear to exert activity against calcium, chloride, potassium and sodium ion channels and also lacks monoamine oxidase (MAO) inhibitory activity4. It was also shown to lack significant activity again the cardiac potassium channel, hERG, in vitro6. Compared to other SNRIs, desvenlafaxine undergoes simple metabolism, has a low risk of drug-drug interactions and does not have to be extensively titrated to reach a therapeutic doseLabel.
- Mechanism of action
Desvenlafaxine, the active metabolite of venlafaxine, is a selective serotonin and norepinephrine reuptake inhibitor3,4,Label. Desvenlafaxine inhibits neurotransmitter reuptake in serotonin, norepinephrine, and dopamine transporters4. Desvenlafaxine inhibits serotonin transporters with 10 times the affinity of norepinephrine transporters, and dopamine transporters with the lowest affinity4. In vitro, desvenlafaxine has no inhibition of monoamine oxidase, and almost no affinity for muscarinic, cholinergic, H1-histaminergic, and alpha1-adrenergic receptors4.
Target Actions Organism ASodium-dependent noradrenaline transporter inhibitorHumans ASodium-dependent serotonin transporter inhibitorHumans USodium-dependent dopamine transporter inhibitorHumans - Absorption
Oral bioavailability is approximately 80%1,4,5 and is unaffected by food. Peak plasma concentration is reached in 7.5 hours5.
- Volume of distribution
3.4L/kgLabel.
- Protein binding
Protein binding is 30% and this is independent of drug concentrationLabel,4,5.
- Metabolism
Desvenlafaxine also undergoes oxidative N-demethylation via cytochrome P450 3A4 to a minor extent4. CYP2D6 is not involved with the metabolism of desvenlafaxine4.
Hover over products below to view reaction partners
- Route of elimination
Desvenlafaxine is mainly excreted in the urine4. 45% of the dose is unchanged in the urine, 19% is excreted as a glucuronide metabolite, and <5% is excreted as N,O-didesmethylvenlafaxine4. No dosage adjustment is necessary for gender, ethnicity, food, or combination with other psychotropics1.
- Half-life
The mean terminal half life is 11.1 hours and may be prolonged in patients with renal and/or moderate to severe hepatic impairment4.
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Desvenlafaxine is excreted in breast milk and as a result, nursing mothers must either stop the drug or stop breast feeding depending on the risks and benefit to mother and childLabel,2.
- Pathways
Pathway Category Venlafaxine Metabolism Pathway Drug metabolism - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when 1,2-Benzodiazepine is combined with Desvenlafaxine. Abacavir Abacavir may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level. Abametapir The serum concentration of Desvenlafaxine can be increased when it is combined with Abametapir. Abciximab The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Abciximab. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Desvenlafaxine. Abiraterone The metabolism of Desvenlafaxine can be decreased when combined with Abiraterone. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Desvenlafaxine. Acarbose The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Acarbose. Acebutolol The serum concentration of Acebutolol can be increased when it is combined with Desvenlafaxine. Aceclofenac The risk or severity of gastrointestinal bleeding can be increased when Desvenlafaxine is combined with Aceclofenac. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Avoid alcohol.
- Avoid St. John's Wort.
- Take with or without food. The absorption is unaffected by food.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Desvenlafaxine fumarate ATX24E9M6L 93414-04-1 SQTJDJZCPOSWSC-WLHGVMLRSA-N Desvenlafaxine fumarate monohydrate R5JHD7L72A 313471-75-9 YETWCSLOYUZBLK-JITBQSAISA-N Desvenlafaxine hydrochloride 3TP4E4F972 300827-87-6 IMWPSXHIEURNKZ-UHFFFAOYSA-N Desvenlafaxine succinate ZB22ENF0XR 386750-22-7 PWPDEXVGKDEKTE-UHFFFAOYSA-N - Product Images
- International/Other Brands
- Khedezla / Zyven-OD
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Desvenlafaxine Tablet, extended release 100 mg/1 Oral Alembic Pharmaceuticals Limited 2013-03-05 Not applicable US 
Desvenlafaxine Tablet, extended release 100 mg/1 Oral Sun Pharmaceutical Industries, Inc. 2013-03-05 Not applicable US 
Desvenlafaxine Tablet, extended release 50 mg/1 Oral Alembic Pharmaceuticals Limited 2013-03-05 Not applicable US Desvenlafaxine Tablet, extended release 100 mg Oral Sanis Health Inc Not applicable Not applicable Canada 
Desvenlafaxine Tablet, extended release 50 mg/1 Oral Sun Pharma Global FZE 2014-01-30 2017-02-04 US Desvenlafaxine Tablet, extended release 100 mg/1 Oral Sun Pharma Global FZE 2014-01-30 2017-02-04 US Desvenlafaxine Tablet, extended release 50 mg/1 Oral Sun Pharmaceutical Industries, Inc. 2013-03-05 Not applicable US 
Desvenlafaxine Tablet, extended release 50 mg Oral Sanis Health Inc Not applicable Not applicable Canada Intelli-desvenlafaxine Tablet, extended release 100 mg Oral Intellipharmaceutics Corp Not applicable Not applicable Canada Intelli-desvenlafaxine Tablet, extended release 50 mg Oral Intellipharmaceutics Corp Not applicable Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ag-desvenlafaxine Tablet, extended release 100 mg Oral Angita Pharma Inc. Not applicable Not applicable Canada Ag-desvenlafaxine Tablet, extended release 50 mg Oral Angita Pharma Inc. Not applicable Not applicable Canada Apo-desvenlafaxine Tablet, extended release 100 mg Oral Apotex Corporation 2017-10-20 Not applicable Canada Apo-desvenlafaxine Tablet, extended release 50 mg Oral Apotex Corporation 2017-10-20 Not applicable Canada Apo-desvenlafaxine Extended-release Tablets Tablet, extended release 100 mg Oral Apotex Corporation 2022-04-26 Not applicable Canada Apo-desvenlafaxine Extended-release Tablets Tablet, extended release 50 mg Oral Apotex Corporation 2022-04-26 Not applicable Canada Desvenlafaxine Tablet, extended release 25 mg/1 Oral Breckenridge Pharmaceutical, Inc 2018-11-28 Not applicable US Desvenlafaxine Tablet, extended release 50 mg/1 Oral Zydus Lifesciences Limited 2018-05-08 Not applicable US Desvenlafaxine Tablet, extended release 50 mg/1 Oral A-S Medication Solutions 2017-03-01 Not applicable US Desvenlafaxine Tablet, extended release 25 mg/1 Oral A-S Medication Solutions 2017-03-01 Not applicable US
Categories
- ATC Codes
- N06AX23 — Desvenlafaxine
- Drug Categories
- Agents producing tachycardia
- Agents that reduce seizure threshold
- Alcohols
- Antidepressive Agents
- Antidepressive Agents Indicated for Depression
- Benzene Derivatives
- Central Nervous System Agents
- Central Nervous System Depressants
- Combined Inhibitors of Serotonin/Norepinephrine Reuptake
- Cyclohexanes
- Cyclohexanols
- Cycloparaffins
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (weak)
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (moderate)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Substrates
- Drugs that are Mainly Renally Excreted
- Fatty Alcohols
- Hexanols
- Hypoglycemia-Associated Agents
- Lipids
- Membrane Transport Modulators
- Nervous System
- Neurotransmitter Agents
- Neurotransmitter Uptake Inhibitors
- Norepinephrine Uptake Inhibitors
- Phenols
- Psychoanaleptics
- Psychotropic Drugs
- Selective Serotonin Reuptake Inhibitors
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Serotonin Agents
- Serotonin and Noradrenaline Reuptake Inhibitors
- Serotonin Modulators
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as cyclohexanols. These are compounds containing an alcohol group attached to a cyclohexane ring.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Alcohols and polyols
- Direct Parent
- Cyclohexanols
- Alternative Parents
- Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Benzene and substituted derivatives / Tertiary alcohols / 1,3-aminoalcohols / Trialkylamines / Cyclic alcohols and derivatives / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- 1,3-aminoalcohol / 1-hydroxy-2-unsubstituted benzenoid / Amine / Aralkylamine / Aromatic homomonocyclic compound / Benzenoid / Cyclic alcohol / Cyclohexanol / Hydrocarbon derivative / Monocyclic benzene moiety
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- tertiary amino compound, phenols, cyclohexanols (CHEBI:83527)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- NG99554ANW
- CAS number
- 93413-62-8
- InChI Key
- KYYIDSXMWOZKMP-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
- IUPAC Name
- 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
- SMILES
- CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1
References
- Synthesis Reference
Karel Pospisilik, Lambertus Thijs, "Process for making desvenlafaxine." U.S. Patent US20070299283, issued December 27, 2007.
US20070299283- General References
- Pae CU: Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8. doi: 10.1517/14656566.2011.636033. [Article]
- Ilett KF, Watt F, Hackett LP, Kohan R, Teoh S: Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression. Ther Drug Monit. 2010 Dec;32(6):704-7. doi: 10.1097/FTD.0b013e3181f88f70. [Article]
- Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ: Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010 Aug;71(8):1088-96. doi: 10.4088/JCP.10m06018blu. [Article]
- Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [Article]
- Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [Article]
- Jasiak NM, Bostwick JR: Risk of QT/QTc prolongation among newer non-SSRI antidepressants. Ann Pharmacother. 2014 Dec;48(12):1620-8. doi: 10.1177/1060028014550645. Epub 2014 Sep 9. [Article]
- FDA Drug Approval Package for Desvenlafaxine [Link]
- External Links
- Human Metabolome Database
- HMDB0060532
- KEGG Drug
- D07793
- PubChem Compound
- 125017
- PubChem Substance
- 99443254
- ChemSpider
- 111300
- BindingDB
- 86748
- 734064
- ChEBI
- 83527
- ChEMBL
- CHEMBL1118
- PharmGKB
- PA165958374
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Desvenlafaxine
- FDA label
- Download (1.02 MB)
- MSDS
- Download (24.1 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Basic Science CYP3A4 Protein, Human / Cytochrome P-450 CYP2D6 / Pharmacokinetics 1 4 Completed Basic Science Pharmacokinetics 1 4 Completed Other Anhedonia / Depression 1 4 Completed Other Healthy Controls / Major Depressive Disorder (MDD) 1 4 Completed Treatment Chronic Depressive Disorder / Persistent Depressive Disorder (Dysthymia) 1 4 Completed Treatment Depression / Methadone Treatment / Opioid Dependence 1 4 Completed Treatment Generalized Anxiety Disorder 1 4 Completed Treatment Major Depressive Disorder (MDD) 5 4 Completed Treatment Social Anxiety Disorder (SAD) 1 4 Recruiting Other Alteration of Cognitive Function / Major Depressive Disorder (MDD) / Neuroticism / Stress (Psychology) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, extended release Oral 25 mg/1 Tablet, film coated, extended release Oral 100 mg/1 Tablet, film coated, extended release Oral 25 mg/1 Tablet, film coated, extended release Oral 50 mg/1 Capsule, extended release Oral 150 mg Tablet, extended release Oral 100 mg/1 Tablet, extended release Oral Tablet, extended release Oral 50 mg/1 Tablet, extended release Oral 100 mg Tablet, extended release Oral 50 mg - Prices
Unit description Cost Unit Pristiq 100 mg extended-release tablet 4.46USD tablet Pristiq 50 mg extended-release tablet 4.31USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region CA2436668 No 2009-05-26 2022-02-11 Canada US6673838 No 2004-01-06 2022-03-01 US US8269040 No 2012-09-18 2027-07-05 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.4 mg/mL ALOGPS logP 2.6 ALOGPS logP 2.29 Chemaxon logS -2.3 ALOGPS pKa (Strongest Acidic) 10.11 Chemaxon pKa (Strongest Basic) 8.87 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 43.7 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 78.54 m3·mol-1 Chemaxon Polarizability 30.32 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9772 Blood Brain Barrier + 0.7722 Caco-2 permeable + 0.8404 P-glycoprotein substrate Substrate 0.6918 P-glycoprotein inhibitor I Non-inhibitor 0.7835 P-glycoprotein inhibitor II Inhibitor 0.5921 Renal organic cation transporter Non-inhibitor 0.5894 CYP450 2C9 substrate Non-substrate 0.7837 CYP450 2D6 substrate Substrate 0.7753 CYP450 3A4 substrate Substrate 0.6997 CYP450 1A2 substrate Non-inhibitor 0.6816 CYP450 2C9 inhibitor Non-inhibitor 0.757 CYP450 2D6 inhibitor Inhibitor 0.6334 CYP450 2C19 inhibitor Non-inhibitor 0.7811 CYP450 3A4 inhibitor Non-inhibitor 0.8646 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8888 Ames test Non AMES toxic 0.8084 Carcinogenicity Non-carcinogens 0.7648 Biodegradation Not ready biodegradable 0.9927 Rat acute toxicity 2.4429 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.6046 hERG inhibition (predictor II) Inhibitor 0.5603
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Norepinephrine:sodium symporter activity
- Specific Function
- Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
- Gene Name
- SLC6A2
- Uniprot ID
- P23975
- Uniprot Name
- Sodium-dependent noradrenaline transporter
- Molecular Weight
- 69331.42 Da
References
- Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. [Article]
- Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [Article]
- Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404. doi: 10.1016/j.clinthera.2009.07.012. [Article]
- Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [Article]
- Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [Article]
- Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serotonin:sodium symporter activity
- Specific Function
- Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
- Gene Name
- SLC6A4
- Uniprot ID
- P31645
- Uniprot Name
- Sodium-dependent serotonin transporter
- Molecular Weight
- 70324.165 Da
References
- Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. Epub 2006 May 4. [Article]
- Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, Blakely RD: Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther. 2007 Nov;323(2):720-9. Epub 2007 Aug 2. [Article]
- Perry R, Cassagnol M: Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther. 2009 Jun;31 Pt 1:1374-404. doi: 10.1016/j.clinthera.2009.07.012. [Article]
- Kamath J, Handratta V: Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. Expert Rev Neurother. 2008 Dec;8(12):1787-97. doi: 10.1586/14737175.8.12.1787. [Article]
- Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [Article]
- Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ: Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Monoamine transmembrane transporter activity
- Specific Function
- Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
- Gene Name
- SLC6A3
- Uniprot ID
- Q01959
- Uniprot Name
- Sodium-dependent dopamine transporter
- Molecular Weight
- 68494.255 Da
References
- Liebowitz MR, Tourian KA: Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry. 2010;12(3). pii: PCC.09r00845. doi: 10.4088/PCC.09r00845blu. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- FDA Drug Approval Package for Desvenlafaxine [Link]
Drug created at May 06, 2010 16:22 / Updated at March 24, 2023 20:20